uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? - uniQure (NASDAQ:QURE)

Core Insights - The stock of uniQure (QURE) surged 26.07% following the departure of Dr. Prasad, as investors believe this will facilitate the regulatory process for the company's Huntington's disease gene therapy, AMT-130 [1] - Despite the short-term rally, QURE's momentum score dropped significantly from 93.8 to 28.01, indicating a complex market sentiment [1][2] - Year-to-date, QURE is down 24.82%, reflecting a long-term downward trend that has not been reversed, although it has seen a 2.86% increase over the last six months and a 47.10% rise over the past year [2][5] Regulatory Environment - Dr. Prasad's exit is viewed as a potential positive change for rare disease therapies, as he had previously imposed stringent requirements for clinical studies, including a randomized, double-blind, sham surgery-controlled study for AMT-130 [3] - Analysts suggest that the new leadership at the FDA's CBER may adopt a more flexible regulatory approach, potentially allowing uniQure to utilize Phase 1/2 data for accelerated approval [4]